• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 9 Oct

    AtlasClear Holdings Announces $20,000,000 Financing

    Investment led by Funicular Funds, LP with insider participation from Sixth Borough Capital $10,000,000 to be invested in the form of convertible debt with a 5-year term at an 11% coupon and a conversion price of $0.75 $10,000,000 (inclusive of $4,250,000 converted from recent debt financing) to be invested in… Read More..

    Share this:
  • 30 Sep

    Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

    Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses observed out to 18 months in adult participants Expected FDA Meeting in Q4 2025 Management to Host Webcast and Conference Call Today at 8:30 A.M. ET… Read More..

    Share this:
  • 30 Sep

    AtlasClear Holdings Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results and Corporate Update

    - Earnings call scheduled for Tuesday, September 30, 2025, at 8:30 a.m. ET - Over $43 million in debt converted, reducing De-SPAC liabilities by more than 80% - Stockholders’ Equity is up over $43 million from Year End 2024 - Third correspondent clearing customer signed to onboard - Extended contract… Read More..

    Share this:
« Previous 1 … 6 7 8 9 10 … 264 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact